Earendil Labs Raises $787M to Expand AI-Driven Biologics Platform

Every so often, a funding round reveals more than capital, it reveals alignment. Earendil Labs just pulled in $787M, with Dimension Capital stepping up alongside DST Global and Hillhouse Investment, and a bench that reads like a biotech and capital markets all-star roster. Sanofi in the mix. Biotech Development Fund backed by Hillhouse and Pfizer. INCE Capital, Luminous Ventures, Miracle Capital. This isn’t a round you celebrate with a press release and a pat on the back. This is the kind you study twice.

Jian Peng and Zhenping Zhu didn’t build a science project. They built a system that treats biology like code and protein design like a language model with consequences. Antibodies, bispecifics, full-stack biologics discovery powered by deep learning and high-throughput validation. Not theory. Production. Over 40 programs moving through the pipeline, with HXN-1001 already stepping into Phase 2 territory. That’s not potential. That’s velocity with direction.

And let’s be honest, biotech has flirted with AI for years. Plenty of slide decks. Plenty of “platform” talk. Earendil Labs is what happens when AI stops being the assistant and starts being the engine. Design, test, learn, repeat. Faster loops. Better molecules. Less guesswork dressed up as genius.

The capital here isn’t just fuel. It’s alignment. You don’t get this mix of investors unless the story holds up under real scrutiny. Global funds, strategic pharma, cross-border firepower between the U.S. and China. That’s not accidental. That’s architecture.

The Sanofi collaboration alone tells you where this is headed. Autoimmune and inflammatory diseases, bispecific antibodies, global development and commercialization baked in. Pair that with WuXi XDC on the ADC side and now you’re not just discovering drugs, you’re wiring them straight into the machinery that gets them to patients.

There’s a lesson sitting under all this if you’re paying attention. The market isn’t rewarding noise. It’s rewarding systems that compound. Earendil Labs didn’t chase headlines. They built leverage. AI that actually ships molecules. Partnerships that actually move programs. Capital that actually accelerates.